利福國際(01212.HK)料中期業績盈轉虧至約2.80億港元
格隆匯7月17日丨利福國際(01212.HK)發佈公告,根據管理層對截至2020年6月30日止六個月的集團未經審核綜合管理賬目進行的初步審閲,集團預期於該期間將錄得公司擁有人應占虧損約2.80億港元,同比去年同期則錄得溢利12.86億港元。
該期間預期虧損主要由於:(1)銷售收入下跌約50%,自2020年1月下旬新型冠狀病毒疫情(2019冠狀病毒)爆發以來導致集團店鋪於該期間客流量大幅減少;(2)集團的金融投資將錄得按市場公平值計價虧損,而去年同期則錄得按市場公平值計價2.74億港元的收益;及(3)集團投資物業將錄得公平值虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.